Subsequently, mammaglobin A was evaluated for detection of minimal residual disease in breast cancer patients [8,26,27], differential diagnosis of metastases and malignant pleural effusions [26-29], and as an immunotherapeutic target in in vitro experiments [30-33] and in vivo animal models [34,35]. Here, SCGB2A2 is linked to breast cancer.